Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Rules and Regulations 9773 

40 CFR Part 70 

Environmental protection, 

Administrative practice and procedure, 

Air pollution control, Intergovernmental 

relations, Operating Permits, Reporting 

and recordkeeping requirements. 

Dated: February 6, 2024. 

David Cash, 

Regional Administrator, EPA Region 1. 

Part 52 of chapter I, title 40 of the 

Code of Federal Regulations is amended 

as follows: 

PART 52—APPROVAL AND 

PROMULGATION OF 

IMPLEMENTATION PLANS 

■ 1. The authority citation for part 52 

continues to read as follows: 

Authority: 42 U.S.C. 7401 et seq. 

Subpart H—Connecticut 

■ 2. Section 52.370 is amended by 

adding paragraph (c)(130) to read as 

follows: 

§ 52.370 Identification of plan. 

* * * * * 

(c) * * * 

(130) Revisions to the State 

Implementation Plan submitted by the 

Connecticut Department of 

Environmental Protection on November 

30, 2023. 

(i) Incorporation by reference. 

(A) Regulations of Connecticut State 

Agencies Section 22a–174–1, 

‘‘Definitions,’’ (106), definition of 

‘‘Severe non-attainment area for ozone.’’ 

(B) Reserved. 

(ii) Additional materials. 

(A) Letter from CT DEEP submitted to 

EPA on November 30, 2023, entitled 

‘‘State Implementation Plan Revision 

Concerning the Definition of Severe 

Non-Attainment Area for Ozone.’’ 

(B) Reserved. 

■ 3. In § 52.385 amended Table 52.385 

by adding a sixth entry for ‘‘22a–174–1’’ 

before the entry for ‘‘22a–174–2’’ to read 

as follows: 

§ 52.385 EPA-approved Connecticut 

regulations. 

* * * * * 

TABLE 52.385—EPA-APPROVED REGULATIONS

Connecticut State 

citation Title/subject 

Dates 

Federal Register 

citation 

Section 

52.370 Date Comments/description 

adopted by 

State 

Date 

approved 

by EPA 

*******

22a–174–1 ............ Definitions ......... 11/13/2023 2/12/2024 [Insert Federal 

Register citation].

(c)(130) Modified definition of ‘‘severe non-attainment area for ozone’’. 

* * * * * * * 

PART 70—STATE OPERATING PERMIT 

PROGRAMS 

■ 4. The authority citation for part 70 

continues to read as follows: 

Authority: 42 U.S.C. 7401, et seq. 

■ 5. Amend Appendix A to Part 70 

under ‘‘Connecticut’’ by adding 

paragraph (b) to read as follows: 

Appendix A to Part 70—Approval 

Status of State and Local Operating 

Permits Programs * * * 

Connecticut 

* * * * * 

(b) Connecticut Department of 

Environmental Protection submitted 

revisions on November 30, 2023 to 

Regulations of Connecticut State Agencies 

Section 22a–174–1, ‘‘Definitions,’’ definition 

of ‘‘Severe non-attainment area for ozone.’’ 

This rule amendment contained in this 

submittal is necessary to make the current 

definition as stringent as the reclassified 

severe nonattainment area in the State of 

Connecticut. The State is hereby granted 

approval effective on March 13, 2024. 

[FR Doc. 2024–02700 Filed 2–9–24; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

40 CFR Part 180 

[EPA–HQ–OPP–2021–0781; FRL–11563–01– 

OCSPP] 

U1-AGTX-Ta1b-QA Protein; Exemption 

From the Requirement of a Tolerance 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Final rule. 

SUMMARY: This regulation establishes an 

exemption from the requirement of a 

tolerance for residues of the U1-AGTXTa1b-QA protein in or on all food 

commodities when used in accordance 

with label directions and good 

agricultural practices. Vestaron 

Corporation submitted a petition to EPA 

under the Federal Food, Drug, and 

Cosmetic Act (FFDCA), requesting an 

exemption from the requirement of a 

tolerance for residues of the U1-AGTXTa1b-QA protein in and on all food 

commodities. This regulation eliminates 

the need to establish a maximum 

permissible level for residues of U1- 

AGTX-Ta1b-QA protein under FFDCA 

when used in accordance with this 

exemption. 

DATES: This regulation is effective 

February 12, 2024. Objections and 

requests for hearings must be received 

on or before April 12, 2024, and must 

be filed in accordance with the 

instructions provided in 40 CFR part 

178 (see also Unit I.C. of the 

SUPPLEMENTARY INFORMATION). 

ADDRESSES: The docket for this action, 

identified by docket identification (ID) 

number EPA–HQ–OPP–2021–0781, is 

available at https://

www.regulations.gov. Please review the 

visitor instructions and additional 

information about the docket available 

at https://www.epa.gov/dockets. 

FOR FURTHER INFORMATION CONTACT: 

Madison Le, Biopesticides and Pollution 

Prevention Division (7511M), Office of 

Pesticide Programs, Environmental 

Protection Agency, 1200 Pennsylvania 

Ave. NW, Washington, DC 20460–0001; 

main telephone number: (202) 566– 

1400; email address: BPPDFRNotices@

epa.gov. 

SUPPLEMENTARY INFORMATION: 

I. General Information 

A. Does this action apply to me? 

You may be potentially affected by 

this action if you are an agricultural 


khammond on DSKJM1Z7X2PROD with RULES
9774 Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Rules and Regulations 

producer, food manufacturer, or 

pesticide manufacturer. The following 

list of North American Industrial 

Classification System (NAICS) codes is 

not intended to be exhaustive, but rather 

provides a guide to help readers 

determine whether this document 

applies to them. Potentially affected 

entities may include: 

• Crop production (NAICS code 111). 

• Animal production (NAICS code 

112). 

• Food manufacturing (NAICS code 

311). 

• Pesticide manufacturing (NAICS 

code 32532). 

B. How can I get electronic access to 

other related information? 

You may access a frequently updated 

electronic version of 40 CFR part 180 

through the Federal Register Office’s eCFR site at https://www.ecfr.gov/ 

current/title-40/chapter-I/subchapter-E/ 

part-180?toc=1. 

C. How can I file an objection or hearing 

request? 

Under FFDCA section 408(g), 21 

U.S.C. 346a, any person may file an 

objection to any aspect of this regulation 

and may also request a hearing on those 

objections. You must file your objection 

or request a hearing on this regulation 

in accordance with the instructions 

provided in 40 CFR part 178. To ensure 

proper receipt by EPA, you must 

identify docket ID number EPA–HQ– 

OPP–2021–0781 in the subject line on 

the first page of your submission. All 

objections and requests for a hearing 

must be in writing, and must be 

received by the Hearing Clerk on or 

before April 12, 2024. Addresses for 

mail and hand delivery of objections 

and hearing requests are provided in 40 

CFR 178.25(b). 

In addition to filing an objection or 

hearing request with the Hearing Clerk 

as described in 40 CFR part 178, please 

submit a copy of the filing (excluding 

any Confidential Business Information 

(CBI)) for inclusion in the public docket. 

Information not marked confidential 

pursuant to 40 CFR part 2 may be 

disclosed publicly by EPA without prior 

notice. Submit the non-CBI copy of your 

objection or hearing request, identified 

by docket ID number EPA–HQ–OPP– 

2021–0781, by one of the following 

methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

online instructions for submitting 

comments. Do not submit electronically 

any information you consider to be CBI 

or other information whose disclosure is 

restricted by statute. 

• Mail: OPP Docket, Environmental 

Protection Agency Docket Center (EPA/ 

DC), (28221T), 1200 Pennsylvania Ave. 

NW, Washington, DC 20460–0001. 

• Hand Delivery: To make special 

arrangements for hand delivery or 

delivery of boxed information, please 

follow the instructions at https://

www.epa.gov/dockets/where-sendcomments-epa-dockets. 

Additional instructions on 

commenting or visiting the docket, 

along with more information about 

dockets generally, is available at https:// 

www.epa.gov/dockets. 

II. Background and Statutory Findings 

In the Federal Register of March 22, 

2022 (87 FR 16133) (FRL–9410–11– 

OCSPP), EPA issued a document 

pursuant to FFDCA section 408(d)(3), 21 

U.S.C. 346a(d)(3), announcing the filing 

of a pesticide tolerance petition (PP 

1F8923) by Vestaron Corporation, 600 

Park Offices Dr., Suite 117, Research 

Triangle Park, NC 27709. The petition 

requested that 40 CFR part 180 be 

amended by establishing an exemption 

from the requirement of a tolerance for 

residues of U1-AGTX-Ta1b-QA protein. 

That document referenced a summary of 

the petition prepared by the petitioner 

Vestaron Corporation, which is 

available in the docket, https://

www.regulations.gov. EPA received one 

comment on the notice of filing. EPA’s 

response to this comment is discussed 

in Unit VII.C. 

III. Final Rule 

A. EPA’s Safety Determination 

Section 408(c)(2)(A)(i) of FFDCA 

allows EPA to establish an exemption 

from the requirement for a tolerance (the 

legal limit for a pesticide chemical 

residue in or on a food) only if EPA 

determines that the exemption is ‘‘safe.’’ 

Section 408(c)(2)(A)(ii) of FFDCA 

defines ‘‘safe’’ to mean that ‘‘there is a 

reasonable certainty that no harm will 

result from aggregate exposure to the 

pesticide chemical residue, including 

all anticipated dietary exposures and all 

other exposures for which there is 

reliable information.’’ This includes 

exposure through drinking water and in 

residential settings, but does not include 

occupational exposure. Pursuant to 

FFDCA section 408(c)(2)(B), in 

establishing or maintaining in effect an 

exemption from the requirement of a 

tolerance, EPA must take into account 

the factors set forth in FFDCA section 

408(b)(2)(C), which require EPA to give 

special consideration to exposure of 

infants and children to the pesticide 

chemical residue in establishing a 

tolerance and to ‘‘ensure that there is a 

reasonable certainty that no harm will 

result to infants and children from 

aggregate exposure to the pesticide 

chemical residue. . . .’’ Additionally, 

FFDCA section 408(b)(2)(D) requires 

that the Agency consider ‘‘available 

information concerning the cumulative 

effects of a particular pesticide’s 

residues’’ and ‘‘other substances that 

have a common mechanism of toxicity.’’ 

EPA evaluated the available 

toxicological and exposure data on U1- 

AGTX-Ta1b-QA protein and considered 

their validity, completeness, and 

reliability, as well as the relationship of 

this information to human risk. A full 

explanation of the data upon which EPA 

relied and its risk assessment based on 

those data can be found within the 

document entitled ‘‘Human Health Risk 

Assessment in Support of the 

Registration of ‘Basin’ End Use Product 

Containing the New Active Ingredient 

U1-AGTX-Ta1b-QA (8.5%) and 

Associated Petition to Establish a 

Permanent Tolerance Exemption’’ 

(Human Health Risk Assessment). This 

document, as well as other relevant 

information, is available in the docket 

for this action as described under 

ADDRESSES. 

Available data have demonstrated 

that, with regard to humans, U1-AGTXTa1b-QA protein is not anticipated to be 

toxic or allergenic via any reasonably 

foreseeable route of exposure. U1- 

AGTX-Ta1b-QA protein is a modified 

form of agatoxin protein derived from 

the venom of the hobo spider (Eratigena 

agrestis) that is intended for control of 

insects and mites. In insects, the 

reported mode-of-action of U1-AGTXTa1b-QA is allosteric inhibition of a 

non-desensitizing nicotinic 

acetylcholine receptor, a neural receptor 

responsible for signal transduction and 

function. The U1-AGTX-Ta1b-QA 

protein binds to a non-signaling portion 

of the target (allosteric) site, altering the 

three-dimensional structure of the 

neural receptor. According to the Center 

of Disease Control (https://

www.cdc.gov/niosh/topics/spiders/ 

types.html), the venom, from which the 

active ingredient is derived, is not 

recognized as toxic to humans. Products 

formulated with U1AGTX-Ta1b-QA will 

be used for foliar applications to plants 

or as a dip/immersion for roots or 

cuttings. 

Toxicological data provided by the 

petitioner indicate that U1-AGTX-Ta1bQA has low acute toxicity via the oral, 

dermal, inhalation, route and it is not a 

dermal or eye irritant. This conclusion 

is further supported by the results of the 

90-day oral toxicity study, prenatal 

development toxicity studies, and the 

absence of genotoxicity in a bacterial 


khammond on DSKJM1Z7X2PROD with RULES
Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Rules and Regulations 9775 

reverse mutation test. In addition, the 

protein sequence of U1-AGTX-Ta1b-QA 

does not show significant homology to 

known allergens and thus there is no 

indication of allergenic cross-reactivity. 

Dietary exposure could occur if U1- 

AGTX-Ta1b-QA is used on crops used 

for food. However, any risks associated 

with dietary exposures are expected to 

be negligible due to the following 

hazard and exposure considerations: 

U1-AGTX-Ta1b-QA (1) has a low overall 

toxicity profile including low toxicity 

via the oral route of exposure; (2) does 

not exhibit protein homology to putative 

or known allergens; (3) does not show 

any prenatal developmental toxicity or 

genetic toxicity; and (4) as described, 

was derived from the venom of the hobo 

spider, which is not recognized as toxic 

to humans. In addition, food crops 

undergo a post-harvest washing process 

to remove soil and surface residues, 

which will therefore reduce the 

amounts of U1-AGTX-Ta1b-QA on the 

treated crops. Root dip and cutting 

immersions, specifically, are expected 

to result in negligible exposure of aboveground grown plant parts used for food 

since these applications occur prior to 

planting and residues are not expected 

to persist on the growing plant. 

Exposure through drinking water is 

expected to be negligible as U1-AGTXTa1b-QA, as a protein, is expected to be 

susceptible to biodegradation in the 

environment as well as water treatment 

processes. 

Non-occupational exposure could 

occur if bystanders are present in areas 

treated with products containing U1- 

AGTX-Ta1b-QA protein. However, 

submitted data have shown that U1- 

AGTX-Ta1b-QA is expected to have low 

toxicity via the oral, dermal, and 

inhalation routes of exposure, is 

minimally irritating to the eyes and 

skin, and is not a dermal sensitizer; 

therefore, any risks from nonoccupational exposure are expected to 

be negligible. 

Based upon the evaluation in the 

Human Health Risk Assessment, which 

found no risk of concern from aggregate 

exposure to U1-AGTX-Ta1b-QA, EPA 

concludes that there is reasonable 

certainty that no harm will result to the 

U.S. population, including infants and 

children, from aggregate exposure to 

residues of U1-AGTX-Ta1b-QA. This 

includes all anticipated dietary 

exposures and all other exposures for 

which there is reliable information. In 

addition, because no threshold effects 

have been identified for infants and 

children, EPA determined that an 

additional Food Quality Protection Act 

(FQPA) safety factor is not necessary to 

protect infants and children from 

anticipated residues of U1-AGTX-Ta1bQA. 

B. Analytical Enforcement Methodology 

An analytical method is not required 

for U1-AGTX-Ta1b-QA since the 

Agency is establishing an exemption 

from the requirement of a tolerance 

without any numerical limitation based 

on a lack of adverse effects. 

C. Response To Comment 

One comment was received during 

the public comment period for the 

notice of filing. The commentor 

provided general objections to EPA 

establishing exemptions from tolerance 

for pesticides but did not provide any 

specific or substantive objections to the 

petition to exempt U1-AGTX-Ta1b-QA 

protein. Based on its review of the data 

and other information submitted in 

support of the tolerance exemption 

petition (as described above in Unit 

III.A), EPA has determined that a 

tolerance exemption for U1-AGTXTa1b-QA protein is safe under the 

FFDCA. Therefore, EPA is establishing a 

tolerance exemption for residues of U1- 

AGTX-Ta1b-QA protein applied to food 

commodities. 

D. Conclusion 

Based on the conclusions detailed in 

Unit III.A., an exemption from the 

requirement of a tolerance is established 

for residues of U1-AGTX-Ta1b-QA 

protein in or on all food commodities 

when used in accordance with label 

directions and good agricultural 

practices. 

IV. Statutory and Executive Order 

Reviews 

This action establishes an exemption 

under FFDCA section 408(d) in 

response to a petition submitted to the 

Agency. The Office of Management and 

Budget (OMB) has exempted these types 

of actions from review under Executive 

Order 12866, entitled ‘‘Regulatory 

Planning and Review’’ (58 FR 51735, 

October 4, 1993). Because this action 

has been exempted from review under 

Executive Order 12866, this action is 

not subject to Executive Order 13211, 

entitled ‘‘Actions Concerning 

Regulations That Significantly Affect 

Energy Supply, Distribution, or Use’’ (66 

FR 28355, May 22, 2001) or Executive 

Order 13045, entitled ‘‘Protection of 

Children from Environmental Health 

Risks and Safety Risks’’ (62 FR 19885, 

April 23, 1997). This action does not 

contain any information collections 

subject to OMB approval under the 

Paperwork Reduction Act (PRA), 44 

U.S.C. 3501 et seq., nor does it require 

any special considerations under 

Executive Order 12898, entitled 

‘‘Federal Actions to Address 

Environmental Justice in Minority 

Populations and Low-Income 

Populations’’ (59 FR 7629, February 16, 

1994). 

Since tolerances and exemptions that 

are established on the basis of a petition 

under FFDCA section 408(d), such as 

the exemption from the requirement of 

a tolerance in this final rule, do not 

require the issuance of a proposed rule, 

the requirements of the Regulatory 

Flexibility Act (RFA) (5 U.S.C. 601 et 

seq.), do not apply. 

This action directly regulates growers, 

food processors, food handlers, and food 

retailers, not States or tribes, nor does 

this action alter the relationships or 

distribution of power and 

responsibilities established by Congress 

in the preemption provisions of FFDCA 

section 408(n)(4). As such, the Agency 

has determined that this action will not 

have a substantial direct effect on States 

or tribal governments, on the 

relationship between the national 

government and the States or tribal 

governments, or on the distribution of 

power and responsibilities among the 

various levels of government or between 

the Federal Government and Indian 

tribes. Thus, the Agency has determined 

that Executive Order 13132, entitled 

‘‘Federalism’’ (64 FR 43255, August 10, 

1999) and Executive Order 13175, 

entitled ‘‘Consultation and Coordination 

with Indian Tribal Governments’’ (65 FR 

67249, November 9, 2000) do not apply 

to this action. In addition, this action 

does not impose any enforceable duty or 

contain any unfunded mandate as 

described under Title II of the Unfunded 

Mandates Reform Act (UMRA) (2 U.S.C. 

1501 et seq.). 

This action does not involve any 

technical standards that would require 

Agency consideration of voluntary 

consensus standards pursuant to section 

12(d) of the National Technology 

Transfer and Advancement Act 

(NTTAA) (15 U.S.C. 272 note). 

V. Congressional Review Act 

Pursuant to the Congressional Review 

Act (5 U.S.C. 801 et seq.), EPA will 

submit a report containing this rule and 

other required information to the U.S. 

Senate, the U.S. House of 

Representatives, and the Comptroller 

General of the United States prior to 

publication of the rule in the Federal 

Register. This action is not a ‘‘major 

rule’’ as defined by 5 U.S.C. 804(2). 

List of Subjects in 40 CFR Part 180 

Environmental protection, 

Administrative practice and procedure, 

Agricultural commodities, Pesticides 


khammond on DSKJM1Z7X2PROD with RULES
9776 Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Rules and Regulations 

and pests, Reporting and recordkeeping 

requirements. 

Dated: January 29, 2024. 

Edward Messina, 

Director, Office of Pesticide Programs. 

Therefore, 40 CFR chapter I is 

amended as follows: 

PART 180—TOLERANCES AND 

EXEMPTIONS FOR PESTICIDE 

CHEMICAL RESIDUES IN FOOD 

■ 1. The authority citation for part 180 

continues to read as follows: 

Authority: 21 U.S.C. 321(q), 346a and 371. 

■ 2. Add § 180.1406 to subpart D to read 

as follows: 

§ 180.1406 U1-AGTX-Ta1b-QA protein; 

exemption from the requirement of a 

tolerance. 

An exemption from the requirement 

of a tolerance is established for residues 

of U1-AGTX-Ta1b-QA protein in or on 

all food commodities when used in 

accordance with label directions and 

good agricultural practices. 

[FR Doc. 2024–02787 Filed 2–9–24; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

42 CFR Parts 405, 410, 411, 414, 415, 

418, 422, 423, 424, 425, 455, 489, 491, 

495, 498, and 600 

[CMS–1784–F2] 

RIN 0938–AV07 

Medicare and Medicaid Programs; CY 

2024 Payment Policies Under the 

Physician Fee Schedule and Other 

Changes to Part B Payment and 

Coverage Policies; Medicare Shared 

Savings Program Requirements; 

Medicare Advantage; Medicare and 

Medicaid Provider and Supplier 

Enrollment Policies; and Basic Health 

Program; Corrections 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), Department 

of Health and Human Services (HHS). 

ACTION: Final rule; correction and 

correcting amendment. 

SUMMARY: This document corrects 

technical and typographical errors in 

the final rule that appeared in the 

November 16, 2023 issue of the Federal 

Register, entitled ‘‘Medicare and 

Medicaid Programs; CY 2024 Payment 

Policies Under the Physician Fee 

Schedule and Other Changes to Part B 

Payment and Coverage Policies; 

Medicare Shared Savings Program 

Requirements; Medicare Advantage; 

Medicare and Medicaid Provider and 

Supplier Enrollment Policies; and Basic 

Health Program’’ (referred to hereafter as 

the ‘‘CY 2024 PFS final rule’’). The 

effective date was January 1, 2024. 

DATES: This correcting document is 

effective February 12, 2024 and is 

applicable beginning January 1, 2024. 

FOR FURTHER INFORMATION CONTACT: 

MedicarePhysicianFeeSchedule@

cms.hhs.gov, for any issues not 

identified below. Please indicate the 

specific issue in the subject line of the 

email. 

MedicarePhysicianFeeSchedule@

cms.hhs.gov, for the following issues: 

caregiver training services, community 

health integration services, and 

principal illness navigation services; 

telehealth and other services involving 

communications technology; PFS 

conversion factor; and PFS payment for 

evaluation and management services. 

Sabrina Ahmed, (410) 786–7499, or 

SharedSavingsProgram@cms.hhs.gov, 

for issues related to the Medicare 

Shared Savings Program (Shared 

Savings Program) Quality performance 

standard and quality reporting 

requirements. 

Janae James, (410) 786–0801, or 

SharedSavingsProgram@cms.hhs.gov, 

for issues related to Shared Savings 

Program beneficiary assignment. 

Frank Whelan (410) 786–1302, for 

issues related to Medicare and Medicaid 

Provider and Supplier Enrollment 

Renee O’Neill, (410) 786–8821, 

MIPSEngagementTeam@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

In FR Doc. 2023–24184 of November 

16, 2023, the CY 2024 PFS final rule (88 

FR 78818), there were technical errors 

that are identified and corrected in this 

correcting document. These corrections 

are applicable as if they had been 

included in the CY 2024 PFS final rule, 

which was effective January 1, 2024. 

II. Summary of Errors 

A. Summary of Errors in the Preamble 

1. On page 78867, in the table titled 

‘‘TABLE 11: CY 2024 Medicare 

Telehealth Services List’’ which 

continues through page 78871, we 

inadvertently omitted four rows of 

services. 

2. On page 78876, second column, 

fourth full paragraph, line 2, we 

inadvertently omitted qualifying 

language before the reference to 

telehealth services and neglected to 

include a reference to further 

background information. 

3. On page 78918, third column, 

second full paragraph, second sentence, 

we neglected to include a clarifying 

phrase. 

4. On page 78920, first column, first 

full paragraph, we inadvertently omitted 

a clarifying phrase. 

5. On page 78944, first column, first 

full paragraph we inadvertently 

included incorrect language in the final 

code descriptor for HCPCS code G0023. 

6. On page 78949, first column, first 

full paragraph, we made a typographical 

error when finalizing limitations on PIN 

services. 

7. On pages 78956 through 78957 in 

the table titled ‘‘TABLE 14: CY 2024 

Work RVUs for New, Revised, and 

Potentially Misvalued Codes,’’ the code 

descriptor listed for HCPCS code G0019 

inadvertently was not updated to reflect 

the final code descriptors as stated in 

the preamble text. 

8. On pages 78958 through 78959 in 

the table titled ‘‘TABLE 14: CY 2024 

Work RVUs for New, Revised, and 

Potentially Misvalued Codes,’’ the code 

descriptors listed for HCPCS codes 

G0022 and G0023 inadvertently were 

not updated to reflect the final code 

descriptors as stated in the preamble 

text. 

9. On pages 78959 through 78960 in 

the table titled ‘‘TABLE 14: CY 2024 

Work RVUs for New, Revised, and 

Potentially Misvalued Codes,’’ the code 

descriptor listed for HCPCS code G0140 

inadvertently was not updated to reflect 

the final code descriptor as stated in the 

preamble text. 

10. On page 78975, we inadvertently 

omitted a sentence to restate the final 

policy we adopted for the inherent 

complexity add-on code (G2211). 

11. On page 79075, third column, first 

full paragraph, line 19, two G-codes for 

PIN services were inadvertently 

omitted. 

12. On page 79112 in the table titled, 

‘‘TABLE 28: Final APP Reporting 

Requirements and Quality Performance 

Standard for Performance Year 2024 and 

Subsequent Performance Years’’, we 

inadvertently included language 

regarding a MIPS Quality performance 

category score. 

13. On page 79112 in the table titled, 

‘‘TABLE 28: Final APP Reporting 

Requirements and Quality Performance 

Standard for Performance Year 2024 and 

Subsequent Performance Years’’, we 

made a typographical error in 

identifying the APP measure. 

14. On page 79113 in the table titled, 

‘‘TABLE 29: Measures included in the 

APP Measure Set for Performance Year 

2024 and Subsequent Performance 


khammond on DSKJM1Z7X2PROD with RULES